ALNYLAM PHARMACEUTICALS, INC.

Pioneering RNAi gene-silencing therapies for rare genetic and cardiometabolic diseases.

ALNY | US

Overview

Corporate Details

ISIN(s):: US72703U1025 (+1 more)
LEI:
Country:: United States of America
Address:: 675 WEST KENDALL STREET, 2142 CAMBRIDGE
Website:: https://www.alnylam.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company pioneering the development and commercialization of RNA interference (RNAi) therapeutics. This novel class of medicines utilizes a natural biological process to silence specific genes, thereby preventing the production of proteins that cause or contribute to human disease. The company's portfolio of approved medicines targets a range of rare genetic, cardiometabolic, and hepatic infectious diseases, with key products including ONPATTRO®, AMVUTTRA®, GIVLAARI®, and OXLUMO®. Alnylam continues to advance a robust clinical pipeline to address diseases with high unmet medical need, solidifying its leadership in translating RNAi science into transformative treatments for patients globally.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all ALNYLAM PHARMACEUTICALS, INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for ALNYLAM PHARMACEUTICALS, INC.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for ALNYLAM PHARMACEUTICALS, INC. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Pentixapharm Holding AG Develops radiopharmaceuticals for diagnosing and treating oncology and adrenal disorders.	Germany	PTP
PeopleBio, Inc. Develops blood tests for early diagnosis of neurodegenerative diseases like Alzheimer's.	South Korea	304840
PEPTONIC Medical AB Develops clinically proven self-care products for women's intimate health.	Sweden	PMED
Peptron, Inc. Develops sustained-release peptide medicines for chronic & neurodegenerative disorders.	South Korea	087010
PERRIGO Co plc World's largest manufacturer of store-brand OTC consumer health products.	United States of America	PRGO
Perseus Proteomics Inc. Develops antibody drugs for cancer, provides research support, and sells diagnostic reagents.	Japan	4882
Personalis, Inc. Cancer genomics & liquid biopsy for early recurrence detection & guiding precision therapies.	United States of America	PSNL
Perspective Therapeutics, Inc. Developing targeted alpha radiotherapies using lead-212 to image and treat solid tumors.	United States of America	CATX
PharmAbcine Inc. Develops antibody therapies for cancer, eye diseases, and vascular-related disorders.	South Korea	208340
Pharma Foods International Co., Ltd. Researches and sells functional ingredients and direct-to-consumer health & beauty products.	Japan	2929